Author

Anders Lundin

AstraZeneca (Sweden)ORCID 0000-0003-3131-8022Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Research Focus:variant calling· 2 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

Marcello MarescaiD· 3 shared Amir Taheri‐GhahfarokhiiD· 2 shared Marie K. SchwinniD· 2 shared Mohammad Bohlooly‐YiD· 2 shared Nina Akrap· 2 shared Pei-Pei Hsieh· 2 shared Thomas Machleidt· 2 shared Abdel Wahad Bidar· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMolecular Biology

Marcello MarescaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular BiologybioRxivPreprintJan 9, 2026

Artemis Regulates Homology-Independent Prime Editing (PRINS) for Enhanced Genomic Insertions

Louis C. Dacquay, Oi Kuan Choong, Angela Membrino…·Marcello Maresca

This study identifies Artemis as a regulator of PRINS editing, showing that modulating Artemis improves insertion efficiency and specificity for genomic engineering.

DOI 10.64898/2025.12.08.693005

humanCRISPR screen

𝕏 PostBluesky

Molecular BiologyNature CommunicationsPeer-reviewedAug 14, 2023

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike A. Firth…·Marcello Maresca

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

137 citationstop 1%

CRISPR screenexperimental assay

𝕏 PostBluesky

GenomicsbioRxivPreprintApr 6, 2020

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal…·Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

2 citations

mousehuman

𝕏 PostBluesky